Nadav Orr, PhD, VP R&D at CollPlant Ltd, joined CollPlant in 2014. He is leading a multidisciplinary R&D team towards the development of technology platforms and clinical applications in the field of regenerative medicine. Prior to this, Nadav served as an Associate Director and Manager of an R&D group at Omrix Biopharmaceuticals Ltd., a subsidiary of ETHICON Biosurgery, a Johnson & Johnson company. While at Omrix, Nadav led an international team developing hemostatic combination products and led base business support for production processes and products. Nadav holds a Ph.D. in immunology from the Weizmann Institute of Science. Nadav will be speaking at the upcoming Biomaterials for 3D Printing webinar.
When was the first encounter you had with 3D printing?
My first encounter with 3D printing in the context of Bioprinting was at the time we initiated our joint work with 3D systems, aiming to utilize their 3D technology to produce tissues and organs for implantation. The experience was that need to spend a lot of effort to educate engineers in biology and biologists engineering in order to bridge the perceptions for problem resolutions.
What inspired you to start your journey in 3D printing?
One of the most exciting things for me in this field is the opportunity to combine the basic sciences of chemistry, biology, and different types of engineering into functional solutions and working products.
Who inspired you the most along this journey in 3D printing ?
I was inspired by the pioneers of 3D printing technology such as Chuck Hull (3d Systems) in one hand who always seek for innovative technical solutions to complex problems and by leaders in the field of tissue regeneration such as Tony Atala that thrive to adopt new technologies for the goal of providing a better solution for patients.
What motivates you the most for your work?
In my work, I am mostly motivated by the opportunity for working together with talented people to offer technology-based solutions for complex problems.
What do you think is (are) the biggest challenge(s) in 3D Printing/bio-printing? What do you think the potential solution(s) is (are)?
I believe that the biggest challenge in developing 3D Printing technology for tissues and organs is to get better understanding of how the combination of physical/mechanical signals and chemical signals drive differential tissue regeneration. Need to continue developing high-throughput vitro 3D systems and correlate the data with in vivo models.
What advice would you give to a smart driven college student in the “real world”? What bad advice you heard should they ignore?
To college and young students I usually advice to plan their early years of high education with courses that will give them broad spectrum of knowledge and hands on experience in different technologies before they choose a long term carrier path. They should not be afraid of changing path just because their default major in the early years at the university.
The worst advice in some cases is to continue your pHD in the same lab you did your Msc just because you get along with you lab mates and not because you identify an exciting scientific topic to dive into.